GLP-1 Chart

Trulicity vs Ozempic

Trulicity vs Ozempic: these brands hold two different GLP-1 medicines, dulaglutide and semaglutide, from two makers.

Prefer

Last updated October 18, 2026. Labels read October 6, 2026.

Learn

More about this page

Both act on the receptor for GLP-1, a gut hormone that raises insulin and lowers glucagon after meals. Both labels are about adults with type 2 diabetes, and both are once weekly shots. This page puts the two FDA labels side by side.

Source: Drucker DJ, Cell Metabolism 2018, PMID 29617641.

The two labels side by side

Label factTrulicityOzempic
Medicine (molecule)dulaglutidesemaglutide
TypeGLP-1
TRULICITY® is a glucagon-like peptide-1 (GLP-1) receptor agonist
GLP-1
OZEMPIC is a glucagon-like peptide 1 (GLP-1) receptor agonist
Maker on the labelEli Lilly and CompanyNovo Nordisk Pharmaceutical Industries, LP
Taken asInjection: pen solution in a single-dose penInjection: pen or prefilled syringe single-patient-use pens ... single-dose prefilled syringe
How often, per labelOnce weekly Administer TRULICITY once weekly, any time of day, with or without food.Once weekly Administer OZEMPIC once weekly, on the same day each week
Approved uses, per label
  • Blood sugar in type 2 diabetes As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus
  • Lower risk of major cardiovascular events To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors
  • Blood sugar in type 2 diabetes as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
  • Lower risk of major cardiovascular events to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease
  • Kidney disease with type 2 diabetes to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease
Boxed warningYes WARNING: RISK OF THYROID C-CELL TUMORSYes WARNING: RISK OF THYROID C-CELL TUMORS
Label readTrulicity label, version 62, effective June 16, 2026Ozempic label, version 20, effective June 1, 2026
FDA approval recordBLA125469, first approved September 18, 2014NDA209637, first approved December 5, 2017

Every line quotes the label. The label links go to the version we read on DailyMed.

What the two labels share

  • The type. Both labels call the medicine a GLP-1 receptor agonist.
  • How often. Both labels say once weekly, as a shot under the skin from a pen.
  • Blood sugar and cardiovascular uses. Both list blood sugar control in type 2 diabetes. Both list lower risk of major cardiovascular events, such as heart attack or stroke, in adults with type 2 diabetes.
  • The boxed warning. Both labels carry a boxed warning about thyroid C-cell tumors.

Where the two labels differ

  • The medicine and maker. Trulicity holds dulaglutide from Eli Lilly. Ozempic holds semaglutide from Novo Nordisk.
  • Who the cardiovascular use covers. Trulicity's label names adults with type 2 diabetes who have established cardiovascular disease or several cardiovascular risk factors. Ozempic's label names adults with type 2 diabetes and established cardiovascular disease. The exact words are in the table.
  • Ages. Trulicity's label includes children 10 and older for blood sugar control. Ozempic's label lists adults.
  • Kidney use. Only the Ozempic label lists a kidney use, for adults with type 2 diabetes and chronic kidney disease.
  • Application type. Trulicity was approved under a biologics license application (BLA) in 2014. Ozempic was approved under a new drug application (NDA) in 2017.

More side by side pages

Ozempic has a brand twin with the same medicine: see Ozempic vs Wegovy. To compare Trulicity with any other label, such as Zepbound or Mounjaro, pick it in the GLP-1 comparison chart. The list of GLP-1 drugs names every brand.

Questions

What is the difference between Trulicity and Ozempic?

Trulicity and Ozempic hold different medicines from different makers: dulaglutide from Eli Lilly and semaglutide from Novo Nordisk. Both labels cover type 2 diabetes. The Ozempic label also lists a kidney use. The Trulicity label also covers children 10 and older for blood sugar control.

Is Trulicity the same as Ozempic?

No. Trulicity and Ozempic are different medicines with different labels. Both labels call their medicine a GLP-1 receptor agonist taken once weekly.

Sources

4 sources with read dates
  1. Trulicity label on DailyMed, Eli Lilly, version 62 of 2026-06-16, read 2026-10-06
  2. Ozempic label on DailyMed, Novo Nordisk, version 20 of 2026-06-01, read 2026-10-06
  3. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1, Drucker DJ, Cell Metabolism 2018, PMID 29617641, abstract read on PubMed 2026-10-06
  4. Drugs@FDA application records for BLA 125469 and NDA 209637, US Food and Drug Administration, via the openFDA drugsfda API, read 2026-10-06